Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 2/20 | 0.51 |
| ▸ | CD38 | P28907 | 1/20 | 0.48 |
| ▸ | KCNQ3 | O43525 | 2/20 | 0.48 |
| ▸ | KCNQ2 | O43526 | 2/20 | 0.48 |
| ▸ | KCNE1 | P15382 | 2/20 | 0.48 |
| ▸ | KCNQ1 | P51787 | 2/20 | 0.48 |
| ▸ | KCNQ5 | Q9NR82 | 1/20 | 0.47 |
| ▸ | GRM4 | Q14833 | 4/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.44 |
| ▸ | NPC1 | O15118 | 2/20 | 0.43 |
| ▸ | RAB9A | P51151 | 2/20 | 0.43 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.43 |
| ▸ | KDR | P35968 | 1/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6003847 | 0.89 | NPC1 (0.57) | MAOBSMN1; SMN2NPC1RAB9ASLC2A1 | |
| SCHEMBL23246094 | 0.88 | RAB9A (0.55) | MAOBCD38KCNQ3KCNQ2KCNE1 | |
| SCHEMBL23246073 | 0.87 | GRM4 (0.57) | MAOBGRM4SMN1; SMN2NPC1RAB9A | |
| SCHEMBL23246072 | 0.82 | GRM4 (0.52) | KCNQ3KCNQ2GRM4SMN1; SMN2NPC1 | |
| SCHEMBL23246051 | 0.81 | SMN1; SMN2 (0.46) | GRM4SMN1; SMN2NPC1RAB9AMEN1 | |
| SCHEMBL23246098 | 0.81 | CFTR (0.49) | KCNQ3KCNQ2KCNE1KCNQ1GRM4 | |
| SCHEMBL168618 | 0.80 | MEN1 (0.63) | KCNQ3KCNQ2KCNE1KCNQ1SMN1; SMN2 | |
| SCHEMBL23245982 | 0.79 | MEN1 (0.46) | GRM4SMN1; SMN2NPC1RAB9AMEN1 | |
| SCHEMBL23246023 | 0.79 | NPC1 (0.53) | SMN1; SMN2NPC1RAB9AMEN1KMT2A | |
| SCHEMBL23245972 | 0.78 | SMN1; SMN2 (0.47) | GRM4SMN1; SMN2NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12528792-B2 | Sulfonamide compounds and the use thereof in the treatment of cancer | TroBio Therapeutics Pty Ltd (AU) | 2026-01-20 | — | — | US | disclosed |
| US-20240317717-A1 | SULFONAMIDE COMPOUNDS AND THE USE THEREOF IN THE TREATMENT OF CANCER | TroBio Therapeutics Pty Ltd (AU) | 2024-09-26 | — | — | US | disclosed |
| EP-4028395-A1 | SULFONAMIDE COMPOUNDS AND THE USE THEREOF IN THE TREATMENT OF CANCER | Trobio Therapeutics Pty Ltd (AU) | 2022-07-20 | — | — | EP | disclosed |
| WO-2021072487-A1 | SULFONAMIDE COMPOUNDS AND THE USE THEREOF IN THE TREATMENT OF CANCER | TroBio Therapeutics Pty Ltd (AU) | 2021-04-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240317717-A1 | SULFONAMIDE COMPOUNDS AND THE USE THEREOF IN THE TREATMENT OF CANCER | STS, TP53, SQOR | MAOB 3812/4885CD38 949/4885KCNQ3 3580/4885 |
| US-12528792-B2 | Sulfonamide compounds and the use thereof in the treatment of cancer | SLC10A6, SLCO4C1, SLCO2A1 | MAOB 1588/4885CD38 1130/4885KCNQ3 2207/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.